Comparable endemic coronavirus nucleoprotein-specific antibodies in mild and severe Covid-19 patients

Susannah Leach, Ali M. Harandi, Tomas Bergström, Lars-Magnus Andersson, Staffan Nilsson, Lia van der Hoek, Magnus Gisslén

Research output: Contribution to JournalArticleAcademicpeer-review

2 Citations (Scopus)


The severity of disease of Covid-19 is highly variable, ranging from asymptomatic to critical respiratory disease and death. Potential cross-reactive immune responses between SARS-CoV-2 and endemic coronavirus (eCoV) may hypothetically contribute to this variability. We herein studied if eCoV nucleoprotein (N)-specific antibodies in the sera of patients with mild or severe Covid-19 are associated with Covid-19 severity. There were comparable levels of eCoV N-specific antibodies early and during the first month of infection in Covid-19 patients with mild and severe symptoms, and healthy SARS-CoV-2-negative subjects. These results warrant further studies to investigate the potential role of eCoV-specific antibodies in immunity to SARS-CoV-2 infection.
Original languageEnglish
Pages (from-to)5614-5617
Number of pages4
JournalJournal of Medical Virology
Issue number9
Early online date2021
Publication statusPublished - Sep 2021


  • COVID-19
  • disease severity
  • endemic coronaviruses
  • nucleoprotein-specific antibodies

Cite this